Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy
- PMID: 17203762
Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy
Abstract
Klatskin-type cholangiocarcinoma is a rare tumor, bearing a very poor prognosis: at diagnosis, most patients can only undergo palliation. Evaluation of outcome, mean survival and quality of life was performed in patients with unresectable hilar cholangiocarcinoma treated with multimodality approach in comparison with surgical palliation, biliary stenting or brachytherapy alone. Twenty-six patients with hilar cholangiocarcinoma were studied: 16 patients were enrolled in the multimodality protocol (bilateral biliary drainage; Iridium-192 brachytherapy; plastic endoprosthesis or metallic stent positioning and external radiotherapy plus systemic chemotherapy), 5 patients underwent surgical palliation and 5 percutaneous decompression alone. Nine patients completed the protocol and 7 were treated with brachytherapy followed by biliary stenting alone. The multimodality approach obtained mean survival (10 months) similar to that for surgery and higher than that of the brachytherapy and metallic stenting groups (6 and 2.75 months, respectively). The average hospital stay (15 days) was lower than that of the surgical group (20 days). A multimodality approach is a suitable alternative to palliative surgery of unresectable hilar cholangiocarcinoma.
Similar articles
-
Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment.Anticancer Res. 2013 Jun;33(6):2747-53. Anticancer Res. 2013. PMID: 23749936
-
Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome.Am J Clin Oncol. 2003 Aug;26(4):422-8. doi: 10.1097/01.COC.0000026833.73428.1F. Am J Clin Oncol. 2003. PMID: 12902899
-
Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach.Gastrointest Endosc. 2009 Jan;69(1):55-62. doi: 10.1016/j.gie.2008.04.005. Epub 2008 Jul 26. Gastrointest Endosc. 2009. PMID: 18657806
-
[Diagnostics and treatment of cholangiocarcinoma].Ned Tijdschr Geneeskd. 2008 May 3;152(18):1037-41. Ned Tijdschr Geneeskd. 2008. PMID: 18547024 Review. Dutch.
-
Palliative management of hilar cholangiocarcinoma.Surg Oncol. 2005 Aug;14(2):59-74. doi: 10.1016/j.suronc.2005.05.004. Surg Oncol. 2005. PMID: 16019208 Review.
Cited by
-
Biliary stenting for unresectable cholangiocarcinoma: A population-based study of long-term outcomes and hospital costs in Taiwan.Kaohsiung J Med Sci. 2015 Jul;31(7):370-6. doi: 10.1016/j.kjms.2015.05.001. Epub 2015 Jun 10. Kaohsiung J Med Sci. 2015. PMID: 26162818 Free PMC article.
-
Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?Oncotarget. 2017 Jul 11;8(28):45335-45344. doi: 10.18632/oncotarget.17336. Oncotarget. 2017. PMID: 28484084 Free PMC article.
-
Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma.J Gastrointest Oncol. 2016 Aug;7(4):580-7. doi: 10.21037/jgo.2016.03.14. J Gastrointest Oncol. 2016. PMID: 27563448 Free PMC article.
-
Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection.Langenbecks Arch Surg. 2017 Feb;402(1):95-104. doi: 10.1007/s00423-016-1542-9. Epub 2016 Dec 23. Langenbecks Arch Surg. 2017. PMID: 28012034
-
Multimodality treatment in unresectable cholangiocarcinoma.J Contemp Brachytherapy. 2020 Apr;12(2):131-138. doi: 10.5114/jcb.2020.94582. Epub 2020 Apr 30. J Contemp Brachytherapy. 2020. PMID: 32395137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical